logo
Arialief Reviews and Complaints 2025: What Science Says About This Neuropathy Relief Supplement (EXPOSED)

Arialief Reviews and Complaints 2025: What Science Says About This Neuropathy Relief Supplement (EXPOSED)

Yahoo13-05-2025

FINDLAY, Ohio, May 13, 2025 (GLOBE NEWSWIRE) -- For years, I've explored every avenue for neuropathy relief—countless supplements, treatments promising quick fixes, and prescriptions that often left me disappointed. When I first encountered Arialief, a nerve health supplement, I was initially skeptical, dismissing it as another passing trend.But Arialief stood out from the rest. Developed with a foundation in medical research and supported by real success stories, it wasn't like the typical health trends I'd tried before. People were reporting genuine relief from neuropathy symptoms—numbness, tingling, and pain—without the usual side effects.
Intrigued but cautious, I decided to commit to Arialief for a thorough 90-day trial. No shortcuts or gimmicks—just a daily routine of Arialief capsules aimed at soothing nerve discomfort and improving overall nerve health.
Here's what happened...
Why I Decided to Try Arialief Supplement
Living with nerve discomfort has been one of the most frustrating health challenges I've faced. The tingling, burning, and numbness in my hands and feet made everyday tasks difficult. I tried stretches, diets, and even medications, but the relief was always short-lived or came with side effects I couldn't tolerate. I started to think I'd just have to live with it.
Then I discovered Arialief, a nerve support supplement designed to help with neuropathy symptoms. What stood out wasn't some flashy promise to 'cure pain fast,' but the way it focused on the root causes—like inflammation, nerve damage, and oxidative stress—using science-backed ingredients.
What really caught my eye were the ingredients: Alpha Lipoic Acid, Magnesium Glycinate, L-Carnitine, and CoQ10. These are known for supporting nerve health, and the formula contains no synthetic fillers or stimulants—just clean, non-GMO compounds designed to work with the body.
I read dozens of real success stories—from a retired nurse who returned to gardening pain-free, to a teacher who could finally sleep through the night without nerve-tingling. It gave me hope.
So I ordered the 3-bottle bundle from the official website and committed to a full 90-day test. With a 60-day money-back guarantee, I figured it was worth trying.
>> Read the consumer report and see how Arialief delivers real changes!
My Full 90-Day Experience with Arialief: A Month-by-Month Breakdown
When I started my 90-day test with Arialief, I was cautiously optimistic. I'd tried several nerve support supplements before—some too weak to notice, others that came with side effects like jitteriness or stomach upset. But Arialief claimed to take a natural, science-backed approach that focused on soothing nerves and supporting healthy circulation. The promise felt realistic, not hyped.
Here's how the journey unfolded for me:
Month 1: Noticing the Small Shifts
I started taking Arialief every morning with a full glass of water. In the first week, I didn't notice anything dramatic, but by the second week, the constant tingling in my feet began to ease up, especially at night. I also noticed slightly better sleep and less restlessness in my legs. While the nerve pain wasn't gone, I felt hopeful—this was the first supplement that didn't upset my stomach or make me feel jittery.
Month 2: Real Improvements
By the second month, the burning sensations in my hands had significantly decreased. I wasn't waking up from discomfort anymore, and simple things like holding a pen or walking barefoot weren't as painful. I also felt more energy throughout the day, which I didn't expect. It felt like Arialief was not just masking symptoms but actually supporting my nervous system.
Month 3: Getting My Life Back
The third month was the most encouraging. The numbness in my toes was now minimal, and I could go on longer walks without the usual discomfort kicking in. My hands felt stronger, and I was even able to return to hobbies like baking and light gardening. What stood out most was the consistency—I didn't have 'bad days' as often, and overall, I felt more in control of my body again.
After 90 days, I can honestly say that Arialief made a real difference. It wasn't a miracle overnight fix, but a steady, reliable solution that helped restore my comfort and confidence.
>> This is exactly what Arialief offers (Check out the evidence)
The Science Behind Arialief: How It Works
Arialief works by addressing the root causes of nerve problems, rather than just masking the symptoms temporarily. The formula contains a carefully selected blend of herbs and minerals that target nerve health and support the nervous system's functions.
These ingredients help reduce inflammation in the nerves, which can lead to damage. Some compounds in Arialief are specifically included to relieve nerve pain and discomfort.
By promoting better blood circulation to the legs and throughout the body, Arialief helps minimize nerve damage and reduce sensations like tingling and burning in the feet. The formula is also rich in antioxidants that combat cell damage and oxidative stress.
With all these elements working together, Arialief supports overall well-being and proper nerve function.
The Key Ingredients in Arialief
Arialief contains a variety of natural ingredients that work together to support nerve health. Each ingredient was carefully selected for its unique benefits. Here's a breakdown of the key components:Primeplam
This exclusive ingredient helps relieve neuropathic pain and discomfort. It works by reducing inflammation in the nerves, protecting them from damage, and alleviating discomfort.
Magnesium Glycinate
This form of magnesium helps to relax muscles, ease tension on the nerves, and calm the nervous system. It also helps reduce anxiety and stress, contributing to an overall improved mood.
Alpha Lipoic Acid
A potent antioxidant, alpha lipoic acid helps protect cells from damage caused by free radicals. This Arialief ingredient fights inflammation and helps reduce oxidative stress throughout the body.
Butcher's Broom
An evergreen shrub native to Europe, butcher's broom contains compounds that help constrict blood vessels, promoting better circulation, especially in the legs. This improved circulation can help relieve nerve pain and numbness.
L-Carnitine
This amino acid plays a key role in energy production and fat metabolism. It helps support the heart, brain, and nerves by providing the energy needed for proper functioning.
Turmeric
The curcumin in turmeric is known for its powerful antioxidant and anti-inflammatory properties. It helps reduce inflammation, protects against cellular damage, and supports the healing of nerve tissues.
>>Try Arialief with a 100% money-back guarantee – results or your money back!
Surprising Benefits of Arialief – What I Didn't Expect
When I began my 90-day journey with Arialief, my main focus was simple: to ease the constant nerve discomfort that had slowly taken over my daily life. What I didn't expect were the unexpected side benefits that began to unfold—quietly at first, then unmistakably.
Here are five surprising changes I experienced while taking Arialief:
1. My sleep became deeper and more restorative.
Within the first couple of weeks, I noticed I was falling asleep faster and waking up feeling genuinely refreshed. For years, nerve-tingling had made it hard to stay asleep through the night. But something about Arialief helped calm that overactive buzzing, especially in my feet. I wasn't tossing and turning anymore—and I started dreaming again.
2. My hands and feet actually felt warm again.
I'd gotten used to that icy-cold sensation in my extremities. I thought poor circulation was just something I had to live with. But around Week 4, I realized my fingertips weren't numb anymore, and my feet weren't freezing under the covers. Arialief seemed to support healthy circulation, and that made a huge difference in my comfort throughout the day.
3. My focus and memory got a quiet upgrade.
I didn't take Arialief expecting a mental clarity boost—but that's what I got. By Month 2, I noticed I could concentrate longer during meetings, remember small details more easily, and finish tasks without getting distracted. When your body isn't overwhelmed by discomfort, your brain has more bandwidth for everything else.
4. My mood felt more balanced and steady.
Living with nerve issues can take a toll on your mental state. The daily frustration and unpredictability used to wear me down. But midway through the second month, I noticed I wasn't snapping as easily or feeling drained emotionally. I was calmer. Arialief helped stabilize my overall mood—likely due to the way it supports the nervous system holistically.
5. I became more physically active—without even trying.
One of the most surprising shifts was how I started moving more, not out of discipline, but because I wanted to. I wasn't avoiding stairs or skipping walks out of fear of triggering pain. I felt stable, supported, and far more confident in my own body. That motivation spilled over into every part of my life.
Arialief gave me more than just relief—it gave me back parts of myself I thought were gone for good. These side benefits weren't advertised, but they've made a lasting difference in how I live day to day.
>> Experience Arialief's powerful benefits and see fast results!
Pros and Cons of Arialief – My Honest Review
After using Arialief for 90 days, I can confidently say it's not just another supplement—it's made a noticeable improvement in my nerve health and overall well-being. However, like any product, it has its strengths and a few areas to consider. Here's a balanced review of both the positives and the aspects to keep in mind.
Pros
Real, science-backed relief
Arialief is rooted in the science of nerve support and healing. It targets nerve discomfort by focusing on neural health and the body's ability to restore itself. Unlike other products that offer vague promises, Arialief uses ingredients that support nerve regeneration and improve circulation. I felt assured about what I was putting in my body.
Support for daily comfort
Arialief didn't just help with nerve discomfort—it supported my overall comfort throughout the day. Whether it was alleviating the tingling sensations in my feet or reducing the daily ache in my hands, Arialief made a noticeable difference in my physical comfort. The improvements were steady, and the relief felt natural.
Mood and emotional balance
I didn't expect such an improvement in my mood, but Arialief helped stabilize my emotions. Stressful days became more manageable, and I felt a calmness I hadn't experienced in a long time. The balanced effects on my nervous system seemed to extend to my emotional state, which was a pleasant surprise.
Simple and easy-to-follow routine
Taking Arialief was straightforward—no complicated protocols or added steps. It seamlessly fits into my daily life without needing major adjustments to my diet or lifestyle. I simply took the supplement and felt the benefits throughout the day.
Real, noticeable results
By the end of the 90 days, I experienced a significant reduction in nerve discomfort, better overall mobility, and improved mood. Arialief didn't just mask symptoms—it contributed to lasting improvements in how I felt and moved every day.
Cons
Price
While Arialief is effective, it's not the cheapest option on the market. The single bottle is pricier than the multi-bottle packages, which offer better value for long-term use. If you're on a tight budget, it's worth considering whether you're ready for the investment.
Takes time to see the results
Arialief is not a quick-fix solution. It took several weeks for me to notice significant improvements in nerve comfort, and the full effects weren't evident until around the 6-week mark. If you're looking for immediate relief, Arialief might not be the right choice. But if you're willing to give it time, the benefits are well worth the wait.
Consistency is essential
To get the most out of Arialief, consistency is key. Skipping doses or not following the recommended routine can reduce its effectiveness. However, with such a simple daily regimen, sticking to it doesn't feel like a burden.
Overall, Arialief has proven to be more than just a nerve health supplement. It's a holistic solution that supported my nerve comfort, improved my mood, and helped me feel better overall. The pros far outweighed the cons, and I highly recommend it to anyone seeking real, lasting improvements in their nerve health and quality of life.
>>Try Arialief risk-free with our 60-day money-back guarantee. If you're not satisfied, we'll refund you
Where to Buy Arialief and Pricing Details
After trying Arialief for a while, I'd definitely recommend purchasing it from the official website, especially for the bundle options that provide the best value.
Currently, Arialief offers three pricing tiers:1 Bottle (30-Day Supply) – $89 + Shipping & Handling
This is the basic option, ideal if you're just starting out, but it's the most expensive per bottle.
3 Bottles (90-Day Supply) – $177 Total ($59/Bottle)
This bundle gives you a significant discount, with FREE shipping and additional bonuses. It's the best value if you're committed to the 90-day supply.
6 Bottles (180-Day Supply) – $294 Total ($49/Bottle)
The best value for long-term users, offering FREE shipping and exclusive bonuses. This is the option I would recommend for those looking for long-term benefits.
[Important Note: Buy from the Official Website]
Who Should Consider Arialief?
Arialief is perfect for anyone dealing with nerve discomfort or those who want to support their overall nerve health. If you've tried other solutions without seeing lasting improvements, Arialief may be the key to resetting your nervous system and promoting long-term relief.
It's also ideal for those who want a natural approach to nerve health without relying on harsh treatments or medications. Arialief works gently with your body to improve comfort and mobility, without the need for drastic lifestyle changes or complex regimens.
However, if you're seeking immediate, short-term relief or a "quick-fix" solution, Arialief may not be the right choice. This supplement works best when taken consistently over time, allowing your body to benefit from its gradual, sustained effects.
Arialief Complaints: What Users Are Saying
While Arialief has received plenty of positive feedback, it's important to consider the full spectrum of user experiences. As with any supplement, there are a few complaints to keep in mind. Here's a look at some common concerns users have raised:
Takes Time to Show Results
Many users have mentioned that Arialief requires patience to see significant results. While the gradual improvement in nerve health and overall well-being is appreciated by some, others were hoping for faster results. For those seeking immediate relief, this slow onset might be a drawback.
Price Point
Some users have noted that Arialief can be on the pricier side compared to other nerve health supplements on the market. While many find the investment worthwhile for the benefits it provides, others feel that the cost may be a barrier, especially if you're looking for a long-term commitment.
Not a Quick-Fix Solution
Arialief isn't marketed as a quick fix, and some users have expressed disappointment that it doesn't provide instant relief from nerve discomfort. It requires regular use and time to show the full effects, which may not meet the expectations of those looking for fast-acting solutions.
Potential for Mild Side Effects
A few users have reported mild side effects like digestive upset or headaches when starting the supplement. While these symptoms usually subside after a few days, they can be a concern for those with sensitive systems or who are new to supplements.
Inconsistent Results
Although many users report positive effects, some have experienced inconsistent results. This could be due to individual differences in how the body responds to the supplement, but it's worth noting that not everyone has the same level of success with Arialief.
>> Find out how Arialief has helped thousands achieve neuropathy relief. Check out the results and testimonials!
Real User Reviews: What People Are Saying
Arialief has been transforming lives, with users reporting remarkable improvements in nerve health, comfort, and overall well-being. Here are a few real testimonials from people who have experienced the benefits:
Emily S., 42, Chicago, IL
"I've been struggling with nerve discomfort for years, and I've tried so many things with little success. After taking Arialief for just a month, I noticed a huge difference. My pain has significantly decreased, and I feel more mobile and comfortable than I have in years. I'm so grateful I gave it a try!"
David R., 55, Austin, TX
"As someone who's dealt with nerve issues and frequent tingling sensations, I was hesitant to try yet another supplement. But Arialief has really made a difference. Not only has it reduced my discomfort, but my energy levels are much better. I can get through the day without feeling drained. I highly recommend it!"
Linda T., 63, Denver, CO
"I was skeptical at first, but Arialief exceeded my expectations. After just a few weeks, the burning sensations in my legs have lessened, and my sleep quality has improved. I feel more at ease and less stressed, knowing that I'm supporting my nerve health in a natural, gentle way."
These testimonials reflect just a small sample of the positive experiences people are having with Arialief. Many users are finding relief and a better quality of life with consistent use.
Final Thoughts on Arialief Reviews
Overall, Arialief has proven to be a genuinely effective solution for managing nerve discomfort and supporting overall nerve health. After a 90-day trial, I've experienced significant improvements in my nerve comfort, mobility, and even mood.
The supplement's science-backed ingredients, such as Alpha Lipoic Acid and Magnesium Glycinate, work gradually to restore balance and promote long-term relief. While the price may be higher than some alternatives, the results justify the investment for those seeking lasting support without harsh medications.
That being said, it's important to remember that Arialief isn't a quick-fix solution. Patience is key, as results take time to manifest. Some users may also experience mild side effects during the initial stages, though these are generally temporary.
Overall, if you're committed to a natural, long-term approach to nerve health, Arialief is a promising choice that has delivered real results for me.
Frequently Asked Questions (Answered)
Is Arialief suitable for vegetarians or vegans?
Yes, Arialief is made with plant-based ingredients and is suitable for both vegetarians and vegans. It does not contain any animal-derived products.
Can I take Arialief if I'm pregnant or breastfeeding?
If you are pregnant or breastfeeding, it's important to consult your doctor before using any supplement, including Arialief, to ensure its safety for both you and your baby.
How should I take Arialief for the best results?
For optimal results, it is recommended to take one capsule of Arialief per day with a meal. Make sure to stay hydrated and maintain a healthy lifestyle, including a balanced diet and regular exercise, to support the effects of the supplement.
Is Arialief safe to use with other medications?
Arialief is made with natural ingredients and is generally considered safe for most users. However, if you are taking prescription medications or have a medical condition, it's always best to consult with your healthcare provider before starting any new supplement to ensure compatibility.
Is there a money-back guarantee for Arialief?
Yes, Arialief offers a 60-day money-back guarantee. If you're not satisfied with the results, you can return the product for a full refund, even if the bottles are empty, as long as it's within the 60-day period.
Email: support@arialief.com
Disclaimer: The information provided about Arialief has not been evaluated by the Food and Drug Administration. This supplement is not intended to diagnose, treat, cure, or prevent any medical condition. Individual results may vary based on factors such as body type, lifestyle, and overall health. It is strongly recommended to consult with a qualified healthcare provider before starting any new supplement, especially if you have preexisting health conditions or are taking medications.
This content is for educational and informational purposes only and should not be considered medical advice. Some links within this article may be affiliate links, meaning we may receive a small commission if you choose to purchase through them, at no extra cost to you. Always seek advice from your healthcare professional before making changes to your wellness routine or supplement regimen.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/71915f91-1e8c-4624-9b01-e743dbb189ca
https://www.globenewswire.com/NewsRoom/AttachmentNg/ec1f2fac-be13-441a-b918-630bb7c33930
https://www.globenewswire.com/NewsRoom/AttachmentNg/92c6f1da-9d88-493c-b7e3-299008fc51f8

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

L&I assists thousands with unemployment compensation claims
L&I assists thousands with unemployment compensation claims

Yahoo

time4 hours ago

  • Yahoo

L&I assists thousands with unemployment compensation claims

Jun. 1—WILKES-BARRE — Now in its third year, the Pennsylvania Department of Labor and Industry's (L&I) UC Connect program continues to provide essential, in-person assistance to Pennsylvanians looking for help navigating the Unemployment Compensation (UC) system. Since its launch in May 2022, UC Connect has helped more than 106,000 Pennsylvanians resolve claims, navigate eligibility issues, and connect to community-based resources, helping more than 700 people in April 2025 alone. Offered at PA CareerLink locations statewide, UC Connect appointments are tailored to claimants who lack reliable internet, are unfamiliar with digital systems, or need language support. With sustained demand for in-person help, L&I has embedded UC Connect into its long-term customer service model. "As UC Connect enters its third year, it remains a necessary and effective tool for delivering unemployment services equitably," said L&I Secretary Nancy A. Walker. "In-person support ensures that no Pennsylvanian is left out of the system simply because they don't have access to broadband or need help understanding the process. L&I has expanded UC Connect's services and took the initiative statewide, and it's clear that our efforts are making a difference in delivering faster, better service for Pennsylvanians." After initially launched as a pilot program in 2022, UC Connect was made a permanent service through bipartisan investments in the 2023 — 24 budget, enabling L&I to hire more than 380 UC interviewers to expand service delivery across Pennsylvania. Unemployment Compensation system update The Department first eliminated a backlog of 40,000 claims from the pandemic era — each requiring case-by-case review — within seven months. The Department then shifted focus to scaling up staff, reducing wait times, and improving access for all Pennsylvanians. Key service highlights from April 2025 include: —Average call wait time was reduced to 18 minutes and 56 seconds. —5,321 live chat sessions were completed—an increase from the same time last year —44,077 new UC claims were filed —$157 million in UC benefits was paid to 99,518 individuals —86,616 helpline calls were answered —13,965 email inquiries were processed —709 individuals received in-person assistance through UC Connect Since the beginning of 2025, L&I has paid out $784 million in UC benefits to more than 483,000 individuals, responded to 361,258 helpline calls, and provided 3,112 UC Connect appointments. Risk-limiting audit of 2025 primary election begins The Department of State this week began Pennsylvania's statewide risk-limiting election audit (RLA) of the May 20 primary. "This is our sixth statewide risk-limiting audit since the 2022 general election," Secretary of the Commonwealth Al Schmidt said. "RLAs are proven to be the highest standard of comprehensive election audits because the RLA process provides a statistically sound, scientific method for confirming, with a high degree of confidence, that the reported outcome of the audited election is accurate." Schmidt said 10 Department employees took turns rolling 10-sided dice to deliver the random 20-digit "seed number," which is used to determine which batches of ballots counties will audit over the next several days. A random-selection drawing on May 23, resulted in the selection of the contest for the Republican nomination for Judge of Commonwealth Court for this RLA. During the audit, county officials will hand-tally the randomly selected ballot batches, then compare those vote counts to the original machine counts for the selected race. Known as a "batch comparison" type of RLA, this pre-certification audit can confirm whether counties accurately tabulated paper ballots so that a full hand count would produce the same reported outcome. The RLA will be carried out in addition to the 2% statutorily required review that counties must perform after each primary and general election in Pennsylvania. For that review, county officials are required to conduct a statistical recount of a random sample of at least 2% of all ballots cast, or 2,000 ballots, whichever is fewer. Counties must complete the RLA by June 5, and they must certify all election results to Schmidt by June 9. Fetterman joins push to return stolen art to Holocaust survivors U.S. Sen. John Fetterman, D-Braddock, is pushing legislation to help survivors of the Holocaust and their families reclaim tens of thousands of pieces of artwork stripped from them by the Nazis. The bill, sponsored by Fetterman and a bipartisan group of lawmakers, attempts to smooth the legal process for these survivors or their heirs as they petition the courts for return of the art, according to a news release. Though Congress passed a bill with the same aim nearly a decade ago, some museums, institutions and governments have stonewalled and battled families in their reclamation efforts, Fetterman's office said. "Some 80 years after the Holocaust, we have a moral responsibility to do right by the victims of these atrocities and their families," Fetterman said in a statement. The proposal extends the original Holocaust Expropriated Art Recovery Act, which is set to expire at the end of 2026. Recognizing the difficulty of tracking down artwork stolen during the Holocaust, Congress in 2016 passed the act to give families six years to file a legal claim for a piece after they've located it. The new bill backed by Fetterman also seeks to make sure families' court claims get fair consideration on their merits rather than being dismissed over technicalities, the release stated. During the Holocaust, Nazi Germany seized hundreds of thousands of pieces of artwork from Jewish people. While the U.S. and other allied nations have tried to restore these valuables to their rightful owners, more than 100,000 pieces still have not been given back, according to Fetterman's office. Fetterman is co-sponsoring the bill introduced by U.S. Sens. John Cornyn, R-Texas, and Richard Blumenthal, D-Connecticut. DCNR: Free menstrual products available in 68 state parks Department of Conservation and Natural Resources (DCNR) Secretary Cindy Adams Dunn this week was joined by First Lady Lori Shapiro and members of the Governor's Advisory Commission on Next Generation Engagement to announce a new initiative that makes free menstrual products available in 68 state parks across Pennsylvania. The products are now stocked in park offices, visitor centers, and environmental educational centers at participating parks, offering a convenient and essential resource for visitors. Signage in English and Spanish helps park-goers locate where products are available. This effort is part of the Shapiro Administration's broader work to make public spaces across the Commonwealth more accessible and supportive for all. The announcement coincides with Menstrual Hygiene Day — highlighting the importance of addressing period poverty through public policy and access. "I've been so inspired by all the young women I've met who are making their voices heard and starting conversations on period poverty — talking so comfortably about something that, for so long, has been a taboo subject," said First Lady Shapiro. "Thanks to them speaking up, Pennsylvania has taken some major steps to ensure more women have access to basic hygiene supplies throughout the day. I want everyone to be able to enjoy their time outdoors, and DCNR's work to get free menstrual products in the bathrooms and visitor offices of our state parks is critical to making our outdoor spaces welcoming to everyone." "No one should have to cut an outdoor adventure short because of their period — DCNR has you covered," said Secretary Dunn. "We are committed to creating inclusive, welcoming outdoor spaces — and that means meeting people's basic needs without stigma or barriers." DCNR will evaluate the program's success and expand it to additional park locations in the future. Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

Yahoo

time6 hours ago

  • Yahoo

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the data presented — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:​HCM; HKEX:​13) announces primary results from the interim analysis of the SACHI Phase III study. These results were presented in a late-breaking oral presentation on Sunday, June 1, 2025, during the American Society of Clinical Oncology ('ASCO') Annual Meeting in Chicago, USA. SACHI is a Phase III study of the savolitinib and osimertinib combination for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor ('EGFR') mutation-positive non-small cell lung cancer ('NSCLC') with MET amplification after disease progression on first-line EGFR inhibitor therapy ( identifier NCT05015608). Title: Savolitinib combined with osimertinib versus chemotherapy in EGFR-mutant and MET-amplification advanced NSCLC after disease progression on EGFR tyrosine kinase inhibitor: Results from a randomized Phase III SACHI study Lead Author: Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Session: Oral Abstract Session: Lung Cancer - Non-Small Cell Metastatic Abstract Number: LBA8505 Date & Time: Sunday, June 1, 2025, 8:00 AM Central Daylight Time Location: Arie Crown Theater Prof. Shun Lu, Chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, and Principal Investigator of the SACHI study, said, 'The results from the SACHI Phase III study represent a significant advancement in the treatment of EGFR mutation-positive NSCLC with MET amplification. The savolitinib and osimertinib combination demonstrates promising efficacy in patients who have progressed on prior EGFR inhibitor therapy. These findings highlight the potential of this novel, chemotherapy-free combination to enable a continued oral regimen, offering a convenient and well-tolerated treatment option that addresses critical unmet needs for patients with this challenging disease.' The event will be held in English and can be accessed via A replay will also be available on the website shortly after the event. As of the interim analysis data cut-off of August 30, 2024, a total of 211 patients were randomized to receive the savolitinib and osimertinib combination or chemotherapy. In the intention to treat (ITT) population, the median progression-free survival ('PFS') assessed by investigator was 8.2 months with savolitinib plus osimertinib, compared to 4.5 months with chemotherapy (hazard ratio ['HR'] 0.34; 95% confidence interval ['CI'] 0.23-0.49; p < 0.0001). The independent review committee ('IRC') assessed median PFS was 7.2 months vs 4.2 months, respectively (HR 0.40; 95% CI 0.28-0.59; p < 0.0001). The investigator-assessed objective response rate (ORR) was 58% in the savolitinib plus osimertinib group compared to 34% for patients in the chemotherapy group. The disease control rate (DCR) was 89% vs 67% and the median duration of response (DoR) was 8.4 months vs 3.2 months, respectively. Overall survival was not mature at the time of the interim analysis. Efficacy outcomes in the third-generation EGFR tyrosine kinase inhibitor ('TKI')–treated patients were comparable with those in the intention-to-treat and third-generation EGFR-TKI–naïve populations. In the third generation EGFR-TKI–treated subgroup, the investigator-assessed and IRC-assessed median PFS were highly consistent, both at 6.9 vs 3.0 months (HR 0.32; p < 0.0001). The safety profile of the savolitinib and osimertinib combination was tolerable and no new safety signals were observed. Treatment-emergent adverse events of Grade 3 or above occurred in 57% of patients in the savolitinib plus osimertinib group compared to 57% for patients in the chemotherapy group, suggesting a favorable safety profile. In January 2025, the Independent Data Monitoring Committee (IDMC) of SACHI has considered that the study has met the pre-defined primary endpoint of PFS in a planned interim analysis and as a result, enrollment into the study has concluded. Supported by data from SACHI, a New Drug Application (NDA) for the combination of savolitinib and osimertinib for the treatment of patients with locally advanced or metastatic EGFR mutation-positive NSCLC with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (NMPA). About Savolitinib Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. MET is a tyrosine kinase receptor that has an essential role in normal cell development. Savolitinib blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. MET overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is a known mechanism of acquired resistance to EGFR TKIs. The prevalence of MET depends on the sample type, detection method and assay cut-off used. Savolitinib is approved in China and is marketed under the brand name ORPATHYS® by our partner, AstraZeneca, for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. It has been included in the National Reimbursement Drug List of China (NRDL) since March 2023. It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers as a single treatment and in combination with other medicines. About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: or follow us on press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / ir@ Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@ Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@ Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500 HSBC Joint Broker Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888 Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500

New Resource from NYC Medical Malpractice Attorney Jonathan C. Reiter Now Available
New Resource from NYC Medical Malpractice Attorney Jonathan C. Reiter Now Available

Business Upturn

time12 hours ago

  • Business Upturn

New Resource from NYC Medical Malpractice Attorney Jonathan C. Reiter Now Available

New York City, NY, June 01, 2025 (GLOBE NEWSWIRE) — In a healthcare system where medical errors rank as the third leading cause of death in America, acclaimed NYC trial attorney Jonathan C. Reiter is jolting listeners from passive acceptance to active vigilance with his groundbreaking new podcast series, 'Understanding Medical Malpractice and Its Impact.' The podcast transforms listeners' mental state from relaxed inattention to focused engagement, delivering critical insights for patients navigating the aftermath of medical negligence – from recognizing when standards of care have been breached to understanding the complex legal landscape of pursuing justice. 'Most patients don't realize they're victims of malpractice until it's almost too late to take action,' says Reiter, whose decades of experience have secured millions in compensation for victims of medical negligence. 'This podcast bridges the knowledge gap that exists between medical professionals and the patients they serve.' The debut episode explores the shocking prevalence of preventable medical errors, including surgical mistakes, misdiagnosis, birth injuries, and medication errors. Reiter provides listeners with a comprehensive framework for identifying potential malpractice and outlines the critical steps patients should take immediately following suspected negligence. 'Understanding the statute of limitations is crucial,' Reiter emphasizes. 'In New York, patients typically have just 2.5 years from the date of malpractice to file a lawsuit, but many victims spend much of that time simply trying to understand what happened to them.' Future episodes will feature interviews with medical experts, patient advocates, and survivors of medical negligence, creating a multifaceted resource for patients and their families. The podcast also examines the broader impact of medical malpractice on the healthcare system and explores potential reforms. With his characteristic clarity and compassion, Reiter transforms complex legal concepts into accessible guidance for listeners. The podcast serves as a natural extension of his commitment to patient advocacy and healthcare accountability. 'Understanding Medical Malpractice and Its Impact' is available now on the website here. About Jonathan C. Reiter Jonathan C. Reiter Law Firm – Top NYC Medical Malpractice Lawyer, Releases New Legal Resource Jonathan C. Reiter is a prominent New York City medical malpractice and personal injury attorney. With over 30 years of experience, he has established himself as one of NYC's premier legal advocates for victims of medical negligence. His firm, the Jonathan C. Reiter Law Firm, PLLC, has secured substantial verdicts and settlements for clients affected by medical errors, helping them rebuild their lives after devastating injuries. Media Contact: Jonathan C. Reiter Law Firm, PLLC T: 212-736-0979 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store